Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Aparicio is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2000 - 2002
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1997 - 2000
Autonomous University of Madrid Class of 1995
Certifications & Licensure
CA State Medical License 1999 - Present
FL State Medical License 2021 - Present
TX State Medical License 2006 - 2027
OK State Medical License 2020 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
- Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2016 May 18
Publications & Presentations
PubMed
- Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.Zhijun Chen, Erolcan Sayar, Daniela Guevara, Helen Richards, Haoyue Zhang
JCI Insight. 2026-10-08 - Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies.Nadeem Bilani, Jesenia M Perez, Ana M Aparicio, Carolina Colli-Cruz, Cora N Sternberg
Cancer Research Communications. 2026-09-29 - Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.Javier Leo, Feiyu Chen, Wei Shi, Xin Liang, Chenling Meng
Oncogene. 2026-09-01
Press Mentions
Subset of Men with Rare Prostate Cancer May Benefit from Immunotherapy Added to Chemotherapy and Targeted Maintenance TherapyMay 30th, 2025- MD Anderson Researchers Showcase Groundbreaking Multi-Cancer Studies at ASCOMay 23rd, 2025
- Paul Viscuse, MD, on Androgen-Indifferent Prostate CancersSeptember 8th, 2021
Grant Support
- Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)UNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
